Does Cyp3a Inducers Interact with Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen?
CDI records a major classification for Cyp3a Inducers and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen. The stored summary is: Coadministration may result in decreased plasma concentrations of RPV and loss of virologic response with possible resistance to RPV or NNRTIs. The mechanism involves rpv is primarily metabolized by cyp3a; inducers increase clearance. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.
- Stored CDI classification
- Major
- Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
RPV is primarily metabolized by CYP3A; inducers increase clearance
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider